Dr. Lacouture is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
16 East 60th Street
New York, NY 10065Phone+1 646-888-6014- Is this information wrong?
Summary
- I am a board-certified dermatologist with special interest in dermatologic conditions that result from cancer treatments. My clinical career has been focused on the recognition and management of side effects affecting the skin, hair, and nails of cancer patients and survivors. These effects can occur as a consequence of chemotherapy, radiation therapy, or therapeutic transplants.
Read less
To ensure that dermatologic side effects do not affect quality of life and the consistent administration of anticancer therapies, I founded the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary effort comprising patient care, education, and research. This clinical program is unique in that it provides pre-treatment counseling and preventive efforts in order to minimize the development of side effects, as well as rapid attention to those patients who develop them. Close communication with treating oncologists ensures that interventions against side effects do not affect the effectiveness of cancer treatments. In summary, the ultimate goal is to ensure the best dermatology-related quality of life and benefit from anticancer treatments.
My research focuses on major components of dermatologic side effects: the accurate description and severity grading; the effects on quality of life; the identification of factors that place individuals at higher risk; and the development of treatments. A basic tenet of this research is in exploring new skin treatments that do not affect the effectiveness of anticancer drugs. For example, we use topical medicines in the face or regional cooling of hands or feet to prevent or treat drug-induced side effects in these areas. A new field being investigated is on dermatologic effects of cancer therapies in long-term cancer survivors, the first step towards ensuring long-term skin health after antineoplastic therapy.
Education & Training
- University of ChicagoResidency, Dermatology, 2002 - 2005
- Cleveland Clinic FoundationInternship, Transitional Year, 2001 - 2002
- Brigham and Women's HospitalRheumatology & Immunology, 1998 - 2001
- Pontifical Xavierian UniversityClass of 1997
Certifications & Licensure
- FL State Medical License 2022 - Present
- CA State Medical License 2004 - Present
- NY State Medical License 2009 - 2024
- CT State Medical License 2023 - 2024
- IL State Medical License 2002 - 2011
- OH State Medical License 2001 - 2002
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014
Clinical Trials
- Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma Start of enrollment: 2008 Jun 01
- Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors Start of enrollment: 2008 Apr 01
- Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.Gallagher, E., Moore, H., Lacouture, M., Dent, S., Farooki, A., Goncalves, M., Isaacs, C., Johnston, A., Juric, D., Quandt, Z., Spring, L., Berman, B., Decker, M., Hor...> ;NPJ Breast Cancer. 2024 Jan 31
- Supportive oncodermatology practices in Europe and the USA.Freites-Martinez, A., Apalla, Z., Fattore, D., Fida, M., Bang, A., Smith, J., Babakoohi, S., Lacouture, M., Sibaud, V.> ;Journal of the European Academy of Dermatology and Venereology. 2023 Dec 6
- 1 citationsPhase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, Daniel J George, Rahul Aggarwal, Elyn Riedel, Takayuki Sumiyoshi, Joseph D Schonhoft, Amanda Anderson, Ninghui M...> ;British Journal of Cancer. 2024 Jan 1
- Join now to see all
Journal Articles
- Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients with CancerMorgan E Freret, Robin H Unger, Kathryn Beal, Suzanne L Wolden, Mario E Lacouture, JAMA Dermatology
- Efficacy of MEK Inhibition in Patients with Histiocytic NeoplasmsRobert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
Books/Book Chapters
Lectures
- Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final r...ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Dermatologic Side Effects of Anticancer Drugs in 2019: What You Need to KnowAmerican Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019
Other
- Pruritus Associated with Targeted Anticancer Therapies and Their ManagementMario Lacouture, MD, ScienceDirect
https://www.doximity.com/articles/8f6f3c0c-ceaa-4ead-9e8b-0096af83d4f7
UpToDate, Wolters Kluwer Health - 2013-02-26
Authored Content
- Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients with CancerAugust 2020
Press Mentions
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast CancerMay 3rd, 2022
- Novel BRAF-Inhibitor Cream Ameliorates Rash from EGFR InhibitorsApril 29th, 2021
- Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast CancerMarch 3rd, 2021
- Join now to see all
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish
Hospital Affiliations
- Memorial Sloan Kettering Cancer CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: